The epidemiology of generalized anxiety disorder in Europe.
about
Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort studyA Single-blinded, Randomized Clinical Trial of How to Implement an Evidence-based Treatment for Generalized Anxiety Disorder [IMPLEMENT]--Effects of Three Different Strategies of Implementation.Economic and humanistic burden of illness in generalized anxiety disorder: an analysis of patient survey data in Europe.Collaborative stepped care for anxiety disorders in primary care: aims and design of a randomized controlled trial.Recognizing and managing anxiety disorders in primary health care in Turkey.Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspectiveAffective concordance in couples: a cross-sectional analysis of depression and anxiety consultations within a population of 13,507 couples in primary care.Prevalence of anxiety disorders among Finnish primary care high utilizers and validation of Finnish translation of GAD-7 and GAD-2 screening tools.Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic, and clinical characteristicsWhite-matter abnormalities in the right posterior hemisphere in generalized anxiety disorder: a diffusion imaging study.Comparative efficacy of the generalized anxiety disorder 7-item scale and the Edinburgh Postnatal Depression Scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum periodEfficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort studyAn international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.Evaluation of Behavioral and Pharmacological Effects of Hydroalcoholic Extract of Valeriana prionophylla Standl. from Guatemala.The adherence/resource priming paradigm--a randomised clinical trial conducting a bonafide psychotherapy protocol for generalised anxiety disorder.Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.Pregabalin for the treatment of generalised anxiety disorder.A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal.The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.Role of pregabalin in the treatment of generalized anxiety disorderClinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients.Specifically altered brain responses to threat in generalized anxiety disorder relative to social anxiety disorder and panic disorderAnxiolytic-like effect of a salmon phospholipopeptidic complex composed of polyunsaturated fatty acids and bioactive peptides.Aberrant Functional Connectivity between the Amygdala and the Temporal Pole in Drug-Free Generalized Anxiety Disorder.Descriptive Epidemiology of Generalized Anxiety Disorder in Canada.Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.New approaches to the pharmacological management of generalized anxiety disorder.Metacognitions in generalized anxiety disorder: theoretical and practical perspectives.The cost effectiveness of pharmacological treatments for generalized anxiety disorder.Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe.The burden of generalized anxiety disorder in Canada.High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis.Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder.Frequency of generalized anxiety disorder in Chinese primary care.Assessment of Anxiety Level of Emergency Health-care Workers by Generalized Anxiety Disorder-7 Tool.
P2860
Q21260318-F7C424E0-B655-4E68-ADA9-656868FD350DQ27311743-6815FC14-ED36-4A9F-A571-7BBDCE235A96Q30799939-9E06C7C1-2DDD-476C-89A9-22D7CBEC7D52Q33500848-4988D175-DC32-43BA-A6FF-600CD2B7A1B2Q33567214-E35328C4-64BB-4EC9-A6F9-EFA65AC35167Q33629375-D9B40E04-CB0F-4B07-AD12-A48AAF4C10C2Q33709176-83E1768A-4E94-4861-B5EA-0E3786899C7BQ33821014-7E990F11-1B00-49C9-8D11-D3574D484905Q33838692-5B81FBAD-E2DB-4145-8662-45788ABD45C4Q33969052-F9D65539-E5C4-4544-971F-F4F2834C7A36Q34083939-BBC317C0-7BAF-499A-B3F5-1DAA8A9F73E5Q34092254-FF3DAA5A-D18D-4786-A777-DD025F046989Q34094392-3655E2B4-3959-48DB-8E67-2F7B09F77FBAQ34230516-35D3860B-10D0-4B5F-BBDA-BF62CB9C826AQ34465555-6FC516B3-A662-4CE6-B838-B2B002334349Q34645876-86886718-299E-44CC-A73D-CFBA84CFF2F5Q35094209-587B088A-08C3-4FB3-970A-77DD0944F13DQ35098087-7090077E-FC12-46D7-9616-6182035BC3B8Q36062003-2F4D12CB-27EF-4B8F-A0AC-C1CC6CCD7BAFQ36205791-D3F19E25-78D7-49E8-9861-D16047AB1D10Q36613951-0490455E-166A-4FD7-8B0B-A44FA00170CAQ36797810-BFD03A09-B39C-4968-9285-9E7C2D51D5E8Q36960563-B78B0814-5FD0-42F7-BFC9-48E2F246F73BQ37125739-1EE8FE6E-F826-403D-81A9-2BF262DDCA9CQ37281390-B350E0EE-8539-4602-939D-877946A39749Q37341043-2B1E5E8B-615C-4037-85E3-16869AB6BC30Q37369792-E3F7D0CC-B0AC-4CCD-941C-3BE5F4A845E2Q37393055-27A5D592-DE0E-4FA7-82CA-8C535AA0F62FQ37635700-76D2A956-0B0B-4E59-BFB6-52DD474ED1BCQ37733559-058042E8-18C1-4A8F-8DD9-093E998EC9BEQ38071131-D21F9780-AEC9-4760-82A6-98DA81D16128Q38078023-1EFAA824-D6DE-4CDB-9580-259D1D18C0B5Q38091323-420A5E3D-764C-4A6B-B92F-19666C412CB1Q38175904-A9CE0A15-82FE-4589-B163-0AA2A29B7B5AQ38905913-F607280E-0993-4E3C-B4D1-72D7B2DCFFE8Q38920965-07C2BB9F-37BC-4E4C-9F5D-70C2DA906618Q39195587-82019361-651B-4CB6-82A7-51386271CDA5Q39479591-8832605F-844A-474C-A2F2-25CFF17C48D4Q39944040-C88F2F16-7BFA-4BBD-9D74-ED7C677686F4Q41515636-04EAF2D3-02C9-442F-BCF8-9A64108B6499
P2860
The epidemiology of generalized anxiety disorder in Europe.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The epidemiology of generalized anxiety disorder in Europe.
@ast
The epidemiology of generalized anxiety disorder in Europe.
@en
The epidemiology of generalized anxiety disorder in Europe.
@nl
type
label
The epidemiology of generalized anxiety disorder in Europe.
@ast
The epidemiology of generalized anxiety disorder in Europe.
@en
The epidemiology of generalized anxiety disorder in Europe.
@nl
prefLabel
The epidemiology of generalized anxiety disorder in Europe.
@ast
The epidemiology of generalized anxiety disorder in Europe.
@en
The epidemiology of generalized anxiety disorder in Europe.
@nl
P2093
P1476
The epidemiology of generalized anxiety disorder in Europe.
@en
P2093
Carlo Altamura
Eni Becker
Roselind Lieb
P304
P356
10.1016/J.EURONEURO.2005.04.010
P407
P577
2005-08-01T00:00:00Z